H. Ballentine Carter, M.D.
H. Ballentine Carter, M.D., is professor of urology and oncology and the director of adult urology at the Johns Hopkins University School of Medicine in Baltimore. He has written extensively on the diagnosis and staging of prostate cancer. In particular, he has performed research on the prostate-specific antigen (PSA) test: how results change as men age; the variability of results in men with prostate cancer; and the test’s use in staging, predicting, and managing prostate cancer.
Dr. Carter chaired the American Urological Association guideline panel that made recommendations for prostate cancer diagnosis. He leads one of the largest active surveillance programs in the United States to monitor men with prostate cancer who do not need immediate treatment. Results from this program have been used to inform guidelines for the management of men with early prostate cancer.
Dr. Carter has had research articles published in a number of publications, including The Journal of Urology, Urology, Cancer Research, The Journal of the American Medical Association (JAMA), the Journal of Clinical Oncology, and the Journal of the National Cancer Institute.
Latest by H. Ballentine Carter, M.D.
Learn more about the risks benign prostatic hyperplasia (BPH) and how you can help prevent it.
For men who have overactive bladder, the goal of a training program is to limit urination to once every two to four hours during the day.
Immunotherapy offers new hope for men with castration-resistant prostate cancer.
If your doctor suspects you have prostate cancer, having an MRI scan might spare you the medical risks of a prostate biopsy.
Prostate cancer is a serious and common health problem among American men. Here's what you should know, including symptoms, screening, and diagnosis.
The TNM staging system describes how far prostate cancer has spread and helps determine appropriate treatment options.
A growing body of research suggests that men who have metabolic syndrome are at increased risk for developing benign prostatic hyperplasia (BPH).
Prostate cancer risk can range from very low to high-risk, and your treatment options depend on where you fall on that scale.
An on-off treatment cycle may help boost your response if androgen treatments are becomming less effective. Here’s what you should know.
Prostate cancer risk can be determined by age, race, and family history, as well as diet and lifestyle factors. Here's what you should know.